Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03726996 · ClinicalTrials.gov registry record · Phase 4
Desipramine in Infantile Neuroaxonal Dystrophy (INAD).
A Phase 4 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 4
- Enrollment target
NCT03726996 is a Phase 4 study that was terminated before completion, run by Duke University. The registered enrollment target is 4 participants.
The verdict
NCT03726996, a Phase 4 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a research study to find out if clinically prescribed desipramine is effective at improving the symptoms and slowing the progression of Infantile Neuroaxonal Dystrophy (INAD) in affected children. Participants will receive an initial oral dose of study drug once a day. This dose may be changed depending on response to study drug Clinically collected data will be recorded for up to 5 years. Investigators will also ask for participant permission to obtain a sample of child's skin biopsy from unused clinical sample previously collected for standard of care.
Interventions
- DRUG Desipramine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-01-14 |
| Est. Completion | 2019-08-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03726996
The ClinicalTrials.gov registry entry for NCT03726996 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Desipramine is the first listed.
NCT03726996 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03726996 about?
NCT03726996 is a clinical study titled "Desipramine in Infantile Neuroaxonal Dystrophy (INAD).". This is a research study to find out if clinically prescribed desipramine is effective at improving the symptoms and slowing the progression of Infantile Neuroaxonal Dystrophy (INAD) in affected children. Participants will receive an initial oral dose of study drug once a day. This dose may be chan...
What is the current status of trial NCT03726996?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 4 participants. The study started on 2019-01-14. Estimated completion is 2019-08-30.
What interventions are being tested in trial NCT03726996?
The interventions under investigation include: Desipramine (DRUG).
Who is sponsoring clinical trial NCT03726996?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.